Editas Medicine (EDIT) Total Non-Current Liabilities (2015 - 2025)

Editas Medicine (EDIT) has 10 years of Total Non-Current Liabilities data on file, last reported at $156.4 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 23.41% year-over-year to $156.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $156.4 million (down 23.41% YoY) and the FY2025 annual result came in at $156.4 million, down 23.41% from the prior year.
• Total Non-Current Liabilities retreated to $156.4 million in Q4 2025 per EDIT's latest filing, from $183.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $204.2 million in Q4 2024 and bottomed at $142.5 million in Q1 2024.
• The 4-year median for Total Non-Current Liabilities is $155.0 million (2022), against an average of $166.8 million.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities jumped 37.76%; it then slipped 23.41% in 2025.
• Tracing EDIT's Total Non-Current Liabilities over 4 years: stood at $153.6 million in 2022, then dropped by 3.5% to $148.3 million in 2023, then soared by 37.76% to $204.2 million in 2024, then retreated by 23.41% to $156.4 million in 2025.
• Per Business Quant, the three latest EDIT Total Non-Current Liabilities figures stand at $156.4 million (Q4 2025), $183.6 million (Q3 2025), and $186.8 million (Q2 2025).

Peer Comparison